Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Burkes Brophy sold 3,235 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $65.09, for a total value of $210,566.15. Following the completion of the transaction, the chief financial officer now owns 92,927 shares in the company, valued at approximately $6,048,618.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Tuesday, January 23rd, Michael Burkes Brophy sold 2,202 shares of Natera stock. The shares were sold at an average price of $65.86, for a total value of $145,023.72.
- On Friday, December 29th, Michael Burkes Brophy sold 1,377 shares of Natera stock. The shares were sold at an average price of $62.29, for a total value of $85,773.33.
Natera Price Performance
NTRA stock opened at $65.94 on Thursday. The business has a fifty day moving average of $61.14 and a two-hundred day moving average of $52.98. The company has a quick ratio of 4.23, a current ratio of 4.37 and a debt-to-equity ratio of 0.36. The stock has a market cap of $7.93 billion, a price-to-earnings ratio of -14.59 and a beta of 1.28. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $68.92.
Institutional Investors Weigh In On Natera
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. abrdn plc acquired a new stake in shares of Natera in the fourth quarter valued at $3,214,000. Oliver Lagore Vanvalin Investment Group grew its stake in shares of Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after buying an additional 389 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Natera by 15.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,844 shares of the medical research company’s stock valued at $1,494,000 after buying an additional 3,228 shares in the last quarter. WCM Investment Management LLC grew its stake in shares of Natera by 101.2% in the fourth quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock valued at $9,058,000 after buying an additional 73,419 shares in the last quarter. Finally, Cerity Partners LLC grew its stake in shares of Natera by 1,043.3% in the fourth quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock valued at $5,664,000 after buying an additional 82,514 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on NTRA. The Goldman Sachs Group raised their target price on Natera from $64.00 to $80.00 and gave the company a “buy” rating in a research report on Monday. UBS Group reduced their price objective on Natera from $76.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th. TD Cowen lifted their price objective on Natera from $82.00 to $87.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. BTIG Research lifted their price objective on Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. Finally, StockNews.com began coverage on Natera in a research report on Thursday, October 5th. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $71.54.
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
- Five stocks we like better than Natera
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- What is a bear market rally? Examples and how they work
- Technology Stocks Explained: Here’s What to Know About Tech
- 7 best bear market ETFs to battle a decline
- 3 Fintech Stocks With Good 2021 Prospects
- 10 best sugar stocks to buy now
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.